The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care CARLSBAD, Calif. , Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. , a leading provider of autoimmune testing, today announced the

Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease CARLSBAD, Calif. , Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. , a leading provider of autoimmune testing, today announced the validation and regulatory submission

CARLSBAD, Calif. , Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services

Expanded AVISE ® CTD trailing twelve-month average selling price Reduced Adjusted EBITDA loss for first three quarters of 2024 Revenue in line with expectations, excluding one-time adjustments CARLSBAD, Calif. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc.

CARLSBAD, Calif. , Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024 , before the market opens on Tuesday, November 12, 2024 . John Aballi , Exagen’s President and Chief

CARLSBAD, Calif. , Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024 , at

CARLSBAD, Calif. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthcare Conference , which takes place September 17-19, 2024 , at the InterContinental Barclay Hotel in

CARLSBAD, Calif. , Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024 . Highlights: Recognized record total revenue of $15.1 million in the second quarter of 2024.

CARLSBAD, Calif. , Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44 th Annual Growth Conference, which takes place August 13-15, 2024 , at the InterContinental Boston Hotel

CARLSBAD, Calif. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black , to the role of Chief Financial Officer (CFO), effective September 1, 2024 . Mr.